Case report: Patient diagnosed with both SM and POTS
A rare presentation of systemic mastocytosis (SM) alongside postural orthostatic tachycardia syndrome (POTS) was recently reported.
A rare presentation of systemic mastocytosis (SM) alongside postural orthostatic tachycardia syndrome (POTS) was recently reported.
Well-differentiated systemic mastocytosis (WDSM), a rare SM variant, was recently associated with previously unknown genetic mutations.
SM is a risk factor for the development of respiratory symptoms, regardless of whether it presents as indolent SM or advanced SM.
A new expanded access program (EAP) has been launched for patients with SM, allowing eligible patients to receive bezuclastinib.
A Phase 2 clinical study called Apex is currently evaluating the safety and efficacy of bezuclastinib in patients with advanced SM.
Mast cells in patients with systemic mastocytosis (SM) appear to express increased levels of galectin-3 and galectin-8.
The use of diagnostic codes for mast cell disorders, such as systemic mastocytosis (SM), appears to be on the rise.
Patients with indolent SM experience significant limitations in their daily lives that directly correlate with symptom burden.
Learn about the current challenges and emergent therapies for bone health in patients with indolent SM.
A recent case study highlights how anemia and low platelet counts can be the initial presentation of systemic mastocytosis (SM).